Koers Jaguar Health Inc Nasdaq
Aandelen
US47008L1061
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 15,11 mln. 14,06 mln. | Omzet 2025 * | 22,66 mln. 21,09 mln. | Marktkapitalisatie | 82,31 mln. 76,6 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -26 mln. -24,19 mln. | Nettowinst (verlies) 2025 * | -21 mln. -19,54 mln. | EV/omzet 2024 * | 5,45 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 3,63 x |
K/w-verhouding 2024 * |
-3,31
x | K/w-verhouding 2025 * |
-4,26
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 92,16% |
Recentste transcriptie over Jaguar Health Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Lisa Conte
FOU | Founder | 65 | 06-06-13 |
Carol Lizak
DFI | Director of Finance/CFO | 60 | 01-05-19 |
Chief Tech/Sci/R&D Officer | 60 | 01-05-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Lisa Conte
FOU | Founder | 65 | 06-06-13 |
James Bochnowski
CHM | Chairman | 80 | 01-02-14 |
John Micek
BRD | Director/Board Member | 71 | 01-04-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+2,93% | 106 mld. | |
+7,02% | 23,47 mld. | |
-14,60% | 21,9 mld. | |
-7,05% | 18,77 mld. | |
-38,55% | 17,85 mld. | |
-8,83% | 16,78 mld. | |
+5,51% | 14,41 mld. | |
+37,49% | 12,86 mld. | |
+329,39% | 8,78 mld. |